Novo Nordisk pays $58.7m to settle claims of mis-selling liraglutideBMJ 2017; 358 doi: https://doi.org/10.1136/bmj.j4214 (Published 08 September 2017) Cite this as: BMJ 2017;358:j4214
- Owen Dyer
The Danish drug company Novo Nordisk has paid $58.7m (£45m; €49m) to settle a cluster of seven US lawsuits accusing the company of deceptive sales practices, paying kickbacks to high prescribing doctors, and playing down the cancer risks of its best selling antidiabetes drug liraglutide (marketed as Victoza).
The company was accused of promoting the off-label use of liraglutide in patients who did not have type 2 diabetes, of paying kickbacks to doctors, and of disguising its sales staff as “diabetes educators” before sending them to doctors’ offices.
But the most serious allegations concerned the company’s …